CVRx’s stock up as heart failure device to be trialled in expanded patient group

CVRx Initiates BENEFIT-HF Trial of Barostim in Expanded Population

January 23, 2026—CVRx, Inc. a developer of neuromodulation solutions for patients with cardiovascular diseases, announced initiation of the BENEFIT-HF clinical trial. According to CVRx, the randomized study is designed to evaluate the impact of the company’s Barostim neuromodulation device in an expanded population of heart failure patients. The Centers for Medicare & Medicaid Services (CMS) has approved category B investigational device exempti…

CVRx’s stock up as heart failure device to be trialled in expanded patient group

CVRx's heart failure device gained approval in the US in 2019 and received CE marking for use in the EU in 2014.The post CVRx’s stock up as heart failure device to be trialled in expanded patient group appeared first on Clinical Trials Arena.